In vitro studies by Fagerhol et al. reveal that patients suffering from multiple myeloma have a higher concentration of S100A12/calprotectin complexes than healthy subjects, and S100A12/calprotectin complexes in this study were used as markers of NET release [39]. This evidence concerns the gene S100A12 and AL amyloidosis.